Assessment of Efficacies of Cardiac Resynchronization Therapies (CRT-P/D) for Heart Failure Patients in China (ADOPT Trial) rationale, design and end-points

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000574

Enrollment

Unknown

Registered

2009-11-06

Start date

2008-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

A:Therapy with CRT

B:Therapy without CRT

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Heart failure patients who must meet all criteria: (1) ischemic or nonischemic cardiomyopathy; (2) NYHA classes III-IV despite OPT; (3) normal sinus rhythm; (4) LVEF=55 mm; (6) and wide QRS complex>=120 ms.

Exclusion criteria

Exclusion criteria: 1. Potentially reversible forms of cardiomyopathy; 2. Cardiac surgery, percutaneous coronary intervention, cardiomyoplasty, myocardial infarction, unstable or severe angina or stroke within 6 weeks before randomization; 3. In-patients requiring continuous intravenous therapy for heart failure; 4. Life expectancy<1 year for disease unrelated to heart failure; 5. Mechanical tricuspid valve; 6. Anticipated problem with compliance; 7. Participation in another trial; 8. Age<18 years old; 9. Women who are pregnant or not using medically acceptable birth control.

Design outcomes

Primary

Measure	Time frame
The composite of all-cause mortality;	—

Secondary

Measure	Time frame
unplanned hospitalisation by cardiovascular reason;Days alive and not in hospital for unplanned cardiovascular cause during the minimum period of follow-up;	—

Countries

China

Contacts

Public Contactwang haichang

wanghc@fmmu.edu.cn+86 029 84773469

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026